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Abstract Mono(6-succinylamido-6-deoxy)-13-cyclodextrin was 
synthesized by classical carbohydrate chemistry and used as a 
template mono-functionalized with the linear, fully flexible 4C- 
spacer carboxylate for covalent linkage of the calpain inhibitor 
leucyl-leucyl-norleucinal. Spectroscopic analyses of the conju- 
gate do not support a self-inclusion of part of the hydrophobic 
peptide tail, but confirm its intra- or intermolecular interaction 
with the template moiety that leads to full water solubility. The 
inhibitory potency of the ~-cyclodextrin/peptide aldehyde con- 
struct was compared with that of the parent Ac-Leu-Leu-Nle-H 
against cathepsin B and calpain. Despite the large size of the 
template the inhibition of cathepsin B was only slightly reduced 
in full agreement with the X-ray structure of this enzyme which 
shows full accessibility of the S-subsites. For this enzyme the 4C- 
spacer is apparently sufficient to guarantee optimal interaction 
of the peptide tail with the binding cleft. Conversely, for g- 
calpain a significantly decreased inhibitory potency was obtained 
with the conjugate suggesting steric interference of the template 
in the binding process. These results show that the beneficial 
properties of the cyclodextrin template can be retained in 
conjugates with bioactive peptides if attention is paid to optimize 
in each case the size and nature of the spacer for optimal 
recognition of the grafted biomolecule. 
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1. Introduction 
Cyclodextrins are cyclic oligosaccharides known for their 
ability to include into their hydrophobic avity via host-guest 
complexation a variety of hydrophobic ompounds [1]. This 
property has been extensively exploited to change the physi- 
copharmaceutical properties of lipophilic drugs such as water 
solubility, bioavailability, improved stability and effectiveness 
[2], and cyclodextrins at present are widely used as transport- 
active additives. The covalent attachment of bioactive pep- 
tides to cyclodextrins has also been proposed [3,4], although 
their grafting to the relatively large cyclodextrin carrier might 
impair recognition by receptor molecules. In fact, covalent 
linkage of an enkephalin analog to [3-cyclodextrin was found 
to lower significantly the receptor affinity and selectivity, but 
the clearance rate was reduced [5]. 
In recent years extensive investigations have been per- 
formed by NMR and X-ray analysis on methylated and un- 
methylated 13-cyclodextrin monosubstituted at the C6 of the 
cyclomaltoheptaose with aromatic chromophores [6], amino 
acids, related derivatives and dipeptides [7-10]. Self-inclusion 
of the grafted moieties was found to depend critically upon 
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the spacer [7,8]. The length and flexibility of the spacer are 
expected to play a similarly decisive role in the mode of pre- 
sentation of grafted biomolecules to the recognition by recep- 
tor molecules. 
In the present study we have examined this aspect by using 
I~-cyclodextrin as template in a conjugate with the well estab- 
lished, but poorly water-soluble calpain inhibitor Ac-Leu-Leu- 
Nle-H [11]. 
2. Materials and methods 
2.1. Materials 
All reagents and solvents used in the synthesis were of the highest 
quality commercially available. The calpain inhibitor Ac-Leu-Leu- 
Nle-H and human cathepsin B (EC 3.4.22.1) were purchased from 
Calbiochem (Bad Soden, Taunus), Z-Phe-Arg-NH-Mec and Suc- 
Leu-Tyr-NH-Mec from Bachem (Heidelberg) and chemicals for buf- 
fers from Sigma (Mi~nchen). Human calpain I (g-calpain) (EC 
3.4.22.17) was isolated from human erythrocytes by B. Gerhartz in 
the laboratory of E.A. Auerswald, Miinchen. 
TLC was carried out on silica gel 60 plates (Merck AG, Darmstadt) 
and compounds were visualized by fluorescamine, chlorine/o-tolidine, 
H2SO4/MeOH; naphthoresorcinol/H3PO4. CE was performed on a 
Spectra Phoresis 1000 capillary electrophoresis apparatus (TSP, 
Darmstadt) at 25 kV using an underivatized fused silica capillary 
(67 cm×75 m; lengthxlD) and 50 mM sodium borate buffer (pH 
8.5); HPLC was carried out with Waters equipment (Eschborn, Ger- 
many) on Nucleosil 300/C8 (Machery and Nagel, Diiren) using a 
linear gradient of acetonitrile/2% H3PO4 from 5:95 to 80:20 in 30 
min. NMR spectra were recorded on Bruker AMX500, FAB-MS 
spectra on Finnigan MAT 900 and MALDI-TOFMS on Bruker Re- 
flex II instruments. CD spectra were measured on a Yobin-Yvon 
dichrograph Mark IV equipped with a thermostated cell holder and 
connected to a data station for signal averaging and processing. All 
data are averages of 10 scans and the spectra were taken at 20°C 
employing quartz cells of 0.2 cm optical path length. The spectra 
are reported in terms of ellipticity units per mol of compounds 
([0]u). The spectra were recorded in water/MeOH (95:5, v/v) and 
concentrations were determined by weight and peptide content as 
determined by quantitative amino acid analysis (6 M HC1; ll0°C; 
48 h); peptide content of Ac-Leu-Leu-Nle-H: 79% and I~-cyclodex- 
trin/Leu-Leu-Nle-H: 77%. 
2.2. Synthesis of the [3-cyclodextrinlL-leucyl-L-leucyl-L-norleucinal con- 
jugate 
Boc-Nle-H was obtained by reduction of the related N-methyl-N- 
methoxy carboxamide with lithium aluminum hydride [12] and con- 
verted to the stereochemically stable semicarbazone Boc-Nle-Sc [13- 
15]. Upon deprotection of the et-amino group with 25% TFA/DCM 
the amino acid semicarbazone H-NIe-Sc was extended to the tripep- 
tide Boc-Leu-Leu-Nle-Sc by standard procedures using Boc-Leu-OSu 
in the acylating steps. Final deprotection again with 25% TFA/DCM 
led to H-Leu-Leu-Nle-Sc.TFA; homogeneous on TLC (CHC13/ 
MeOH/H20, 80:40:6; CHCla/MeOH/pyridine/H20, 60:15:2:1); 
FAB-MS: mlz=399.4 ([M+H]+); calcd, for C19HzsN603: 398.3; 
1H-NMR (d6-DMSO) was consistent with the structure. 
Mono(2,3 - di- O-acetyl-6-deoxy-6-amino)hexakis(2,3,6-tri- O-acetyl)- 
13-cyclodextrin was synthesized according to known procedures [16,17] 
and then reacted in pyridine with 1.5 equiv, succinic anhydride. Upon 
removal of the excess anhydride by washings of the AcOEt solution 
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with a 5% KHCO3 solution the succinylated derivative was isolated 
by flash chromatography (eluent: toluene/EtOH, 2:1) in 85% yield; 
homogeneous on TLC (toluene/EtOH, 2:1; Rf 0.43); XH-NMR (de- 
DMSO): ~5= 1.97-2.07 (m, 60H), 2.31 (br s, 4H), 3.60-4.50 (m, 28H), 
4.64-4.81 (m, 7H), 5.01-5.10 (m, 7H), 5.14-5.26 (m, 7H), 7.72 (br s, 
1H); FAB-MS: mlz=2113.0 (37%, [M+K]+), 2097.0 (40%, 
[M+Na]+), 2075.0 (100%, [M+H]+), 2057.1 (21%, [M+H-H20]+); 
calcd, for Cs6HnsO~TN: 2073.61. 
Deacetylation of mono(2,3-di-O-acetyl-6-deoxy-6-succinylamido)- 
hexakis(2,3,6-tri-O-acetyl)-~-cyclodextrin was performed with KOH 
in aqueous MeOH for 4 h, then the reaction mixture was diluted 
with water and treated with Amberlyst 15. Mono(6-deoxy-6-succinyl- 
amido)-13-cyclodextrin was isolated in 98% yield from the concen- 
trated aqueous olution by precipitation with acetone; homogeneous 
on TLC (acetonitrile/H20, 7:3; Re 0.26), HPLC (tR 6.85 min) and CE 
(tM 5.28 rain); 1H-NMR (D20): 8=2.50--2.65 (m, 4H), 3.33 (dd, 1H), 
3.46 (t, 1H), 3.56-3.74 (m, 12 H), 3.80-4.06 (m, 28 H), 5.02-5.20 (m, 
7H); FAB-MS: mlz=1310.O (33%, [M--H+2K]+), 1272.2 (100%, 
[M+K]+), 1234.1 (30%, [M+H]+); calcd, for C46HT~OzTN: 1233.40. 
The mono-functionalized ~-cyclodextrin was coupled overnight 
with H-Leu-Leu-Nle-Sc trifluoroacetate in DMF with PyBOP [18] 
upon neutralization with TEA. The cyclodextrin/peptide conjugate 
was obtained by direct precipitation from water with acetone in 
68% yield; homogeneous on TLC (acetonitrile/H20, 7:3; Rf 0.42), 
HPLC (tR 13.12 min) and CE (tM 4.40 min); FAB-MS: 
re~z= 1614.9 (71%, [M+H]+); calcd, for C65HmO3oN7: 1613.69. The 
semicarbazone d rivative was hydrolyzed in MeOH with acetic acid in 
presence of formaldehyde and the desired 13-cyclodextrin/tripeptide 
aldehyde conjugate was isolated from water by precipitation with 
acetone in 72% yield; homogeneous on TLC (acetonitrile/H20, 7:3; 
Rf 0.46), HPLC (linear gradient from 100% A to 100% B in 30 rain; 
trt 13.12 rain) and CE (tM 4.45 min); aH-NMR (D20): ~=0.88-1.07 
(m, 15H), 1.17-1.90 (m, 12H), 2.47-2.80 (m, 4H), 3.07-3.14 (rn, 1H), 
3.40~.10 (m, 42H), 4.28~,.42 (m, 2H), 4.97 (d, 1H hydrated alde- 
hyde), 5.05-5.18 (m, 7H), 9.50 (s, 1H, aldehyde); FAB-MS: 
m/z= 1557.3 (18%, [M+H]+), 1539.3 (100%, [M+H-H20]+), MAL- 
DI-TOFMS: mlz=1579.6 [M+Na] +, 1595.6 [M+K]+; calcd, for 
C64H108039N4 : 1556.65. 
2.3. NMR spectroscopy 
NMR spectra of the l]-cyclodextrin/Leu-Leu-Nle-H conjugate were 
recorded at 500 MHz in d6-DMSO (5 mM) and water (10 mM, 10% 
D20/90% H20). For 1D and 2D proton spectra the following param- 
eters were used. 1D 1H-NMR (d6-DMSO): 400 acquisitions, ize 16K, 
sweep width 7575.7 Hz; TOCSY [19,20] (ds-DMSO): mixing time for 
MLEV17 40 ms, trim pulse 2.5 ms, size 2K, sweep width 7575.7 Hz in 
tl and t2, 64 acquisitions, 512 increments [21]; NOESY [22] 
(d6-DMSO): mixing time 150 ms, size 2K, sweep width 7575.7 Hz in 
tl and t2, 64 acquisitions, 512 increments [21]; 1D IH-NMR (water): 
with presaturation, 64 acquisitions, weep width 7575.7 Hz, size 16K 
and with jump return pulse sequence [23] and same parameter as with 
presaturation; TOCSY [19,20] (water): with presaturation, mixing 
time for MLEV17 40 ms, trim pulse 1.5 ms, size 2K, sweep width 
7575.7 Hz in tl and t2, 96 acquisitions, 416 increments (TPPI) [24]; 
NOESY [22] (water): with jump return pulse sequence [23], mixing 
time 200 ms, size 2K, sweep width 7575.7 Hz in t1 and t2, 96 acquisi- 
tions, 512 increments (TPPI); ROESY [25] (water): 150 ms spin-lock 
with water suppression, 96 acquisitions, size 2K, 512 increments 
(TPPI), spin-lock power 4 kHz, sweep width 7575.7 Hz in tl and 
t2; prior to transformation of the TOCSY, NOESY and ROESY 
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spectra gaussian window function in t2 and shifted sine-bell function 
in tl were used. 
2.4. Determination of kinetic constants 
Continuous fluorometric nhibition assays were performed and eval- 
uated as described in detail elsewhere [26,27]. Inhibition of cathepsin 
B (27 pM) was assayed at 12 and 30°C with the substrate Z-Phe-Arg- 
NH-Mec (10 ~tM) in 1.2 ml of 0.3 mM sodium acetate buffer (pH 5.5) 
containing 2 mM EDTA, 0.015% Brij-35, 1 mM dithiothreitol (added 
freshly), 1% DMSO (from added substrate solution). The inhibitors 
Ac-Leu-Leu-Nle-H (dissolved in DMSO) and 13-cyclodextrin/Leu-Leu- 
NIe-H (dissolved in water) were added in 1 10 ~1 aliquots resulting in 
final concentrations of 1-125 nM in the assay. Inhibition of calpain 
(10-15 nM) was measured at 12°C with the substrate Suc-Leu-Tyr- 
NH-Mec (250 I.tM) in a total volume of 1.2 ml of 50 mM Tris-HC1 
(pH 7.5) containing 100 mM NaCI, 1 mM dithiothreitol (added 
freshly), 200 I.tM CaCI~, 0.015% (by vol.) Brij-35 and 1% DMSO 
(from the substrate solution). After 10-15 min, when calpain was fully 
activated and the rate of substrate release constant, inhibitor solutions 
(1-10 I.tl) were added resulting in final concentrations of 0.14).3 I.tM 
for Ac-Leu-Leu-Nle-H and of 0.4-10 ~tM for ~-cyclodextrin/Leu-Leu- 
Nle-H. 
The rate constants kon, ko~ (mechanism A), ks, k6 (mechanism B), 
and the dissociation constant of the initial complex, Ki (mechanism 
B), were obtained from the presteady-state phase of the progress 
curves as described by Morrison [28]. The equilibrium dissociation 
constant for mechanism A was calculated from the rate constants 
(Ki=ko~/ko~) or measured in steady-state inhibition experiments 
when the presteady-state phase was too fast to be resolved. For mech- 
anism B the overall inhibition constant Ki* was calculated from the 
equation: Ki* = Ki'k6/(k5 +k6) [28]. 
3. Results and discussion 
To allow for flexible display of the tripeptide aldehyde Leu- 
Leu-Nle-H in the conjugate, the mono(6-succinylamido-6- 
deoxy)-I]-cyclodextrin containing a 4C-spacer was synthesized 
by classical methods of carbohydrate chemistry as outlined in 
Fig. 1. The intermediate mono(6-azido-6-deoxy)-I]-cyclodex- 
trin was peracetylated prior to the phosphine-mediated reduc- 
tion of the azido group to the amino function and subsequent 
acylation with succinic anhydride in order to avoid formation 
of succinic acid esters. Deacetylation generated the ~-cyclo- 
dextrin derivative mono-functionalized at the linear, fully flex- 
ible 4C-spacer as carboxylic acid. The tripeptide aldehyde H- 
Leu-Leu-Nle-H was prepared as the semicarbazone according 
to known procedures [12-15] and was then linked to the cy- 
clodextrin derivative via the PyBOP procedure [18]. Forma- 
tion of intra- and/or intermolecular ester bonds with the free 
hydroxyl functions was not observed to occur under these 
conditions. Finally, weak acid hydrolysis of the semicarba- 
zone in the presence of excesses of formaldehyde led to the 
desired conjugate in good overall yield as a homogeneous and 
well characterized compound. 
Table 1 
Kinetic constants for the inhibition of cathepsin B and la-calpain by the ~-cyclodextrin/Leu-Leu-Nle-H conjugate and Ac-Leu-Leu-Nle-H 
Cathepsin B Ix-Calpain 
kon (X10 -5) koff (×10 4) Ki (nM) Ki (nM) k~ ()<10 a) k6 (×10 4) Ki* (nM) 
(M-1 s-q) (s -1) (s -1) (s -1) 
[3-Cyclodextrin/ 30°C 8.5 _+ 0.54 (9) 
Leu-Leu-Nle-H 12oC 0.40+0.0064 0.8+0.10 2.0 (8) 3470+449 3.7+0.77 1.0 +0.16 91 (6) 
Ac-Leu-Leu-Nle-H 30°C 2.2 _+ 0.055 (15) 
12°C 2.80+0.064 2.8+0.12 1.0 (11) 122+26 2.8+0.28 0.77+0.16 3.2 (7) 
See Section 2.4 for experimental conditions and definition of constants. The best estimates obtained by nonlinear egression analysis are given 
together with their standad errors and the number of experiments (in parentheses). 
N. Schaschke t al./FEBS Letters 391 (1996) 297-301 
1D and 2D 1H-NMR spectra were recorded in DMSO and 
water in the attempt o define the mode of display of the 
peptide moiety on the cyclodextrin template. TOCSY and 
NOESY spectra (data not shown) allowed us to assign all 
resonances of the tripeptide aldehyde including the spacer 
residue. Moreover, with the 1D and TOCSY spectra in 
H20/D20 quantification of the hydrated (87%) and non-hy- 
drated aldehyde (13%) was achieved. With the TOCSY and 
NOESY spectra, however, only a partial assignment of the 
carbohydrate moiety could be achieved in both solvents. 
The carbohydrate signals were found to be more dispersed 
in water than in DMSO. While the anomeric protons of the 
seven glucopyranose units overlap in water (8= 5.18-5.05 
ppm), the residual protons of the modified unit are partly 
well separated. Mono-attachment of the peptide moiety to 
the symmetric yclodextrin molecule via the succinyl spacer 
leads to an asymmetric cyclodextrin derivative with concomi- 
tant partial resolution of the resonances in the 1D 1H-NMR 
spectrum. This dispersion may, therefore, not necessarily re- 
flect self-inclusion of the peptide as suggested previously in 
mono-derivatized cyclodextrins [29,30]. The NOESY spectra 
in both solvents and the ROESY spectrum in water show 
sequential NH-CHtx, NH-side-chain and NH-spacer NOEs 
(ROEs) within the peptide chain and the spacer esidue. The 
amide proton of the derivatized glucopyranose unit exhibits 
several NH-carbohydrate proton NOEs, whereas no NOE 
could be detected from the peptide backbone amides as well 
as from the CHc~ protons to the carbohydrate moiety. The 
absence of these NOEs in water and DMSO would exclude 
self-inclusion of part of the peptide chain. However, the weak 
NOEs observed between the methyl groups of the leucine and/ 
or norleucine side chains to the carbohydrate portion are 
supportive of an interaction of the peptide with the cyclodex- 
trin surface in a manner similar to the capped structural mod- 
el [7]. Apparently, this type of interaction is sufficient o con- 
vert the poorly water-soluble Ac-Leu-Leu-Nle-H into a fully 
water-soluble cyclodextrin conjugate. 
A comparison of the CD spectrum computed from the 
spectra of mono(6-deoxy-6-succinylamido)-[~-cyclodextrin 
and Ac-Leu-Leu-Nle-H with that of the [3-cyclodextrin/Leu- 
Leu-Nle-H conjugate shows that the dichroic contributions of 
the two component parts are not additive (Fig. 2). A notice- 
able red shift of the negative nn* maximum with a strong 
increase in intensity is observed that would be consistent 
with a less hydrophilic environment of the peptide backbone 
[31] and thus with the capped structural model in which the 
peptide portion is interacting with the top of the cylindrical 
cyclodextrin. 
Regarding the inhibitory potency of the tripeptide aldehyde 
when covalently linked to 13-cyclodextrin, it showed the same 
reversible slow-binding inhibition of cathepsin B and Ix-caP 
pain as Ac-Leu-Leu-Nle-H. Under the experimental condi- 
tions used the inhibition of cathepsin B by both tripeptide 
aldehydes follows a simple single-step mechanism A [28], 
whereas the inhibition of calpain by both inhibitors was de- 
scribed best by the mechanism B [28] where a rapidly formed 
initial complex (Ki) is slowly converted to a tightened complex 
(Ki*). The molecular basis of this two-step mechanism is not 
known. 
The inhibition constants (Ki) of Ac-Leu-Leu-Nle-H and its 
[3-cyclodextrin conjugate determined in the present study (Ta- 
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Fig. 1. Synthesis of the ~-cyclodextrin/Leu-Leu-Nle-H conjugate. 
for the calpain inhibitor (150 nM for cathepsin B and 190 nM 
for calpain I [11]). These differences might be explained by the 
fact that the former values were obtained in stopped assays 
rather than by detailed kinetic analysis. In control experi- 
ments [3-cyclodextrin (up to 100 ktM) did not affect he activity 
of cathepsin B and calpain. The related kinetic data confirm 
that potential complexation of the substrate and/or of the 
released fluorophore by the cyclodextrin does not disturb 
the measurements, although such complexation is known to 
affect both the intensity and location of the fluorescence emis- 
sion maxima of sequestered fluorophores [32]. Moreover, in- 
hibition of both enzymes by Ac-Leu-Leu-Nle-H was not af- 
fected when [~-cyclodextrin (up to 10 ktM) was added to the 
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Fig. 2. CD spectra of Ac-Leu-Leu-Nle-H ( . . . .  ), mono(6-succiny- 
lamido-6-deoxy)-13-cyclodextrin ( . . . . . . . .  ) and of the ~-cyclodex- 
trin/Leu-Leu-Nle-H conjugate ( ) in water/MeOH (95:5); for 
comparison the spectrum computed from the dichroic contributions 
of the two component parts ( . . . . .  ). 
assays. These results confirm that the observed inhibition is 
completely due to the peptide aldehyde moiety of the ~-cyclo- 
dextrin conjugate. 
As indicated by the dissociation constants (Ki), the affinity 
of the tripeptide aldehyde for cathepsin B is only 2-4-fold 
reduced upon its conjugation to the 13-cyclodextrin template 
(see Table 1). The slightly weaker inhibition of cathepsin B by 
the ~-cyclodextrin conjugate compared to the free tripeptide 
aldehyde is mainly due to its 7-fold lower association rate 
constant compared to the 3.5-fold lower koff rate. The lower 
ko~ rate could derive from some steric hindrance in the bind- 
ing process that results from the bulky cyclodextrin template. 
Conversely, the lower koff rate would indicate a contribution, 
although weak, of the cyclodextrin moiety in stabilizing the 
enzyme/inhibitor complex, An inspection of the X-ray struc- 
ture of human cathepsin B [33] reveals as peculiar feature of 
this enzyme the presence of an occluding loop with two his- 
tidines which limits C-terminally the size of the substrate, 
whereas the S-subsites are easily accessible and similar to 
the binding cleft in papain. In the X-ray structure of the 
papain/stefin B complex [34] the P1 and P2 side chains interact 
tightly with the related enzyme binding subsites, but the P3 
side chain of methionine was already found to be only in a 
loose contact with the enzyme surface. Since a substrate-like 
binding is expected for the tripeptide aldehyde, the 4C-spacer 
used in the cyclodextrin-conjugate is apparently fully sufficient 
for optimal binding of the inhibitor portion. 
The calpain activity is known to be rather quickly destroyed 
by autolysis of the Ca2+-activated nzyme. Therefore, pre- 
steady-state inhibition kinetics with calpain could be mea- 
sured only by lowering the temperature to 12°C where the 
rate of substrate release was found to be nearly constant 
over a period of 2 h. Under these conditions the covalently 
attached 13-cyclodextrin template ffected a 28-fold higher dis- 
sociation constant of the initial enzyme-inhibitor complex (Ki) 
and of the tightened complex (Ki*), respectively, whereas it did 
not affect significantly the rate constants of the slow conver- 
sion between the two complexes (k~, k6). Unfortunately, the 
X-ray structure of calpain is not yet available; thus a rational 
explanation of the experimental data is not possible, although 
the strongly reduced inhibition potency of the tripeptide alde- 
hyde in the conjugate would primarily suggest sterically hin- 
dered access to the binding cleft. 
The results presented in this study show that the highly 
promising properties of cyclodextrin/bioactive peptide conju- 
gates can be exploited with minimal loss of bioactivity if at- 
tention is paid to optimize in each case the spacer in order to 
allow for recognition of the grafted biomolecule. 
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